Related Experiment Video
Updated: Apr 29, 2026

Anti-Nuclear Antibody Screening Using HEp-2 Cells
Published on: June 23, 2014
Differences in SARS-CoV-2 Antigen Persistence in Individuals With Systemic Autoimmune Rheumatic Diseases Compared to
Naomi J Patel1,2,3, Zoe Swank3,4,5, Jiaqi Wang2
1Division of Rheumatology, Inflammation, and Immunity, Mass General Brigham, Boston, Massachusetts.
Objective:
Individuals with systemic autoimmune rheumatic diseases (SARDs) are at risk for worse acute and post-acute COVID-19 outcomes, though whether individuals with SARDs have longer persistence of viral antigens after COVID-19 has not been studied.
Methods:
This retrospective cohort study evaluated post-COVID-19 differences in SARS-CoV-2 antigen (spike, spike protein that contains the receptor-binding domain, and nucleocapsid) positivity between individuals with SARDs (COVID-19 and Rheumatic Diseases [RheumCARD]) and without SARDs (Researching COVID to Enhance Recovery [RECOVER]-Adult). SARS-CoV-2 antigens were measured in collected samples using a validated ultrasensitive single molecule array. This digital enzyme-linked immunosorbent assay used antibody-coated magnetic beads to capture antigen molecules, which were loaded into microwell arrays and detected through enzymatic cleavage of a fluorescent substrate. We used logistic regression to estimate unadjusted and adjusted (for age, sex, infection year, vaccination status, and COVID-19 treatment) odds ratios for SARS-CoV-2 antigen positivity at months 3 and 6 following COVID-19.
Results:
Among 210 individuals with SARDs in RheumCARD and 348 individuals without SARDs in RECOVER-Adult, any SARS-CoV-2 antigen positivity was more common in those with SARDs (36.7% in RheumCARD vs 18.9% in RECOVER-Adult; P < 0.001). Those with SARDs had higher odds of nucleocapsid antigen positivity (adjusted odds ratio [aOR] 3.73, 95% confidence interval [CI] 1.28-10.85) or any antigen positivity (aOR 2.89, 95% CI 1.43-5.85) three months after COVID-19 infection and higher odds of nucleocapsid antigen positivity (aOR 6.62, 95% CI 1.09-40.30) six months after COVID-19 infection.
Conclusion:
Individuals with SARDs were more likely to have SARS-CoV-2 antigen positivity at months 3 and 6 following COVID-19 infection compared with individuals without SARDs, not explained by demographics, variant, vaccination, or treatment.
More Related Videos
Related Concept Videos
Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune...
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Immunological Memory
What is Immunological Memory?
Immunological memory is an integral function of the immune system that allows it to recognize and react more rapidly and effectively to pathogens previously encountered. This feature...
Antigens Involved in Adaptive Immunity
Complete Antigens
Complete antigens possess both immunogenicity and...
Diversity of Antigen Receptors
Before encountering any antigen, lymphocytes express these receptors. On B cells, the antigen receptor is a membrane-bound antibody molecule called BCR; on T cells, it is a T cell receptor or TCR. B and T cell receptors are composed of two...
Rheumatic Heart Disease I: Introduction

